Home › Categories › Corporate Reports› View Announcement

View Announcement.pdf

02741464.pdf

🔗 Source: wcsecure.weblink.com.au

📊 Size: 237 KB

👤 Author: User

⬇️ Downloads: 184

Summary

Actinogen Medical Limited held its Annual General Meeting on November 17, 2023, where all 12 resolutions were passed on a poll, with Resolutions 4, 11, and 12 being passed by a sufficient majority as special resolutions. The company is developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, with its lead compound Xanamem being assessed for Alzheimer's Disease and Depression. Xanamem's mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11β-HSD1 enzyme in the brain. The company has studied Xanamem in over 300 volunteers and patients, finding statistically significant improvements in working memory and attention, and is conducting a series of Phase 2 studies to further confirm its therapeutic potential.

Download File

Description

Actinogen Medical Limited held its Annual General Meeting on November 17, 2023, where all 12 resolutions were passed on a poll, with Resolutions 4, 11, and 12...

Technical Information

File Format: PDF
File Size: 237 KB
Pages: 4
Language: EN
Author: User
Total Downloads: 184
Last Updated: 1 week ago

Document Overview

This PDF document about View announcement provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into View announcement.